NCT00127127View on ClinicalTrials.gov

A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029)

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 10, 2005

Primary Completion Date

August 21, 2009

Study Completion Date

August 21, 2009

Conditions
Tumors
Interventions
DRUG

vorinostat

vorinostat 100 mg, 200 mg, 400 mg, or 500 mg single oral dose; once-daily or twice-daily administration

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00127127 - A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029) | Biotech Hunter | Biotech Hunter